Patents Assigned to Valneva Austria GmbH
-
Patent number: 11951163Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: GrantFiled: March 6, 2023Date of Patent: April 9, 2024Assignee: Valneva Austria GMBHInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
-
Publication number: 20240108712Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: ApplicationFiled: June 14, 2023Publication date: April 4, 2024Applicant: Valneva Austria GmbHInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
-
Publication number: 20240026412Abstract: The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).Type: ApplicationFiled: April 9, 2021Publication date: January 25, 2024Applicant: Valneva Austria GmbHInventors: Robert Schlegl, Franz Moisi, Markus Hanner, Urban Lundberg
-
Publication number: 20230398210Abstract: The present invention relates to an aluminum composition for use as an adjuvant or for use in a method of vaccination, the use of an alum-adjuvanted vaccine composition comprising less than 1.25 ppb copper for increasing bioavailability of an antigen in the vaccine, wherein the antigen is a protein, particularly an OspA protein or a Clostridium difficile toxin A and toxin B fusion protein or a SARS-CoV-2 protein or an hMPV protein, in an aluminum-containing vaccine composition and the use of a radical quenching compound such as L-methionine for increasing bioavailability of a protein antigen in a copper- and aluminum-containing vaccine composition.Type: ApplicationFiled: April 9, 2021Publication date: December 14, 2023Applicant: Valneva Austria GmbHInventors: Robert Schlegl, Jürgen Heindl-Wruss
-
Publication number: 20230322869Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: January 6, 2023Publication date: October 12, 2023Applicant: Valneva Austria GmbHInventors: URBAN LUNDBERG, Wolfgang Schüler
-
Publication number: 20230295245Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 14, 2022Publication date: September 21, 2023Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20230226165Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: ApplicationFiled: March 6, 2023Publication date: July 20, 2023Applicant: Valneva Austria GmbHInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
-
Patent number: 11684669Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: GrantFiled: September 10, 2021Date of Patent: June 27, 2023Assignees: Valneva Austria GmbH, Dynavax Technologies CorporationInventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
-
Publication number: 20230173052Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.Type: ApplicationFiled: September 9, 2022Publication date: June 8, 2023Applicants: VALNEVA AUSTRIA GMBH, VALNEVA USA, INC.Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
-
Publication number: 20230173051Abstract: The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.Type: ApplicationFiled: April 9, 2021Publication date: June 8, 2023Applicants: Valneva Austria GmbH, Pfizer Inc.Inventors: Nicole Bézay, Romana Hochreiter, Urban Lundberb, Steven Russell Bailey, Annaliesa Sybil Anderson, Kathrin Ute Jansen, Daniel Alfred Scott
-
Publication number: 20230151063Abstract: The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.Type: ApplicationFiled: April 13, 2018Publication date: May 18, 2023Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Andreas Meinke, Abhijeet Nayak, Wolfgang Schüler
-
Publication number: 20230092650Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.Type: ApplicationFiled: March 1, 2021Publication date: March 23, 2023Applicants: Dynavax Technologies Corporation, Valneva Austria GmbHInventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
-
Publication number: 20230038284Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: ApplicationFiled: September 10, 2021Publication date: February 9, 2023Applicants: Valneva Austria GmbH, Dynavax Technologies CorporationInventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
-
Patent number: 11572392Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: August 11, 2020Date of Patent: February 7, 2023Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 11524064Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.Type: GrantFiled: July 13, 2020Date of Patent: December 13, 2022Assignee: Valneva Austria GmbHInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
-
Patent number: 11478540Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.Type: GrantFiled: August 19, 2021Date of Patent: October 25, 2022Assignees: Valneva Austria GmbH, Valneva USA, Inc.Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
-
Patent number: 11466058Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: December 4, 2019Date of Patent: October 11, 2022Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20220298493Abstract: Described herein are methods for inactivation of viruses with high yield and recovery, and compositions produced by such methods.Type: ApplicationFiled: March 8, 2022Publication date: September 22, 2022Applicant: Valneva Austria GmbHInventors: Robert Schlegl, Jürgen Heindl-Wruss
-
Publication number: 20220273786Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: ApplicationFiled: December 13, 2021Publication date: September 1, 2022Applicant: Valneva Austria GmbHInventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
-
Publication number: 20220185851Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: November 2, 2021Publication date: June 16, 2022Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel